Key result
Type 1 VWD endothelial cells showed transcriptome-wide differences versus controls, with 64 mRNAs and 7 miRNAs differentially regulated during basal VWF release.
Why the study?
Current diagnostic guidelines only consider basal VWF levels despite poor correlation with bleeding severity, and pathogenic mechanisms of defects in stimulated VWF release in type 1 VWD remain poorly defined.
Case-Control (n=12)
Transcriptome-wide differences exist between type 1 VWD and control ECFCs during basal and stimulated VWF release, which may contribute to bleeding phenotypes and reveal novel therapeutic targets.
May identify mechanisms of stimulated VWF release in type 1 VWD; hypothesis-generating and should not yet change practice.
Type 1 von Willebrand disease (VWD) is associated with a reduction in qualitatively normal von Willebrand factor (VWF). Current diagnostic guidelines only take into consideration the contribution of basal VWF levels, despite a lack of correlation with bleeding severity. Defects in stimulated VWF release, which occurs after hemostatic challenge, may contribute to bleeding in type 1 VWD, but the pathogenic mechanisms are poorly defined. In this study, a layered multiomic approach including messenger RNA (mRNA) and microRNA (miRNA) sequencing was used to evaluate transcriptome-wide differences between type 1 VWD- and control-derived endothelial colony forming cells (ECFCs) during basal and stimulated VWF release. ECFCs from 8 patients with type 1 VWD and 4 other patients were included in this study as controls. VWF protein analysis revealed heterogenous responses to stimulation among type 1 VWD and control ECFCs. During basal VWF release, 64 mRNAs and 7 miRNAs were differentially regulated between type 1 VWD and control ECFCs, and 65 putatively pathogenic miRNA-mRNA interactions were identified. During stimulated VWF release, 190 mRNAs and 5 mRNAs were differentially regulated between type 1 VWD and control ECFCs, and 110 putatively pathogenic miRNA-mRNA interactions were identified. Five gene ontology terms including coagulation, regulation of cell shape, and regulation of cell signaling were also differentially regulated in type 1 VWD ECFCs during stimulated release. To our knowledge, we have shown for the first time that transcriptome-wide differences exist between type 1 VWD and control ECFCs. These differences may contribute to bleeding in type 1 VWD, and further investigation may reveal novel biomarkers and therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Kloosterman et al. (2022) conducted a case-control in Type 1 von Willebrand disease (n=12). Type 1 VWD vs. Controls was evaluated on Differentially regulated mRNAs and miRNAs during basal and stimulated VWF release. Type 1 VWD endothelial cells showed transcriptome-wide differences versus controls, with 64 mRNAs and 7 miRNAs differentially regulated during basal VWF release.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: